The Role of Anti-B Cell Activating Factor Therapy for Treating Lupus Nephritis
- PMID: 36302568
- PMCID: PMC9718047
- DOI: 10.2215/CJN.11340922
The Role of Anti-B Cell Activating Factor Therapy for Treating Lupus Nephritis
Keywords: belimumab; immunosuppression; systemic lupus erythematosus; voclosporin.
Comment on
-
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.Clin J Am Soc Nephrol. 2022 Nov;17(11):1620-1630. doi: 10.2215/CJN.02520322. Epub 2022 Oct 27. Clin J Am Soc Nephrol. 2022. PMID: 36302567 Free PMC article. Clinical Trial.
Similar articles
-
Will New Treatment Options for Lupus Nephritis Be Affordable?Clin J Am Soc Nephrol. 2022 Mar;17(3):340-341. doi: 10.2215/CJN.00690122. Epub 2022 Feb 4. Clin J Am Soc Nephrol. 2022. PMID: 35121594 Free PMC article. No abstract available.
-
Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis.Curr Opin Rheumatol. 2020 Nov;32(6):609-616. doi: 10.1097/BOR.0000000000000754. Curr Opin Rheumatol. 2020. PMID: 33002950 Review.
-
The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States.Clin J Am Soc Nephrol. 2022 Mar;17(3):385-394. doi: 10.2215/CJN.13030921. Epub 2022 Feb 3. Clin J Am Soc Nephrol. 2022. PMID: 35115304 Free PMC article.
-
B-cell depletion or belimumab or voclosporin for lupus nephritis?Curr Opin Nephrol Hypertens. 2021 Mar 1;30(2):237-244. doi: 10.1097/MNH.0000000000000662. Curr Opin Nephrol Hypertens. 2021. PMID: 33186226 Review.
-
Belimumab for the treatment of pediatric patients with lupus nephritis.Expert Opin Biol Ther. 2023 Mar;23(3):243-251. doi: 10.1080/14712598.2023.2178297. Epub 2023 Feb 17. Expert Opin Biol Ther. 2023. PMID: 36750049 Clinical Trial.
Cited by
-
Therapeutic progress in the targeting of B cells in lupus nephritis: pathogenesis to clinical research.Int Urol Nephrol. 2025 Apr 29. doi: 10.1007/s11255-025-04441-1. Online ahead of print. Int Urol Nephrol. 2025. PMID: 40299182 Review.
References
-
- Anders H-J, Saxena R, Zhao M-H, Parodis I, Salmon JE, Mohan C: Lupus nephritis. Nat Rev Dis Primers 6: 7, 2020 - PubMed
-
- Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae S-C, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin P, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcón GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz- Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V: The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology (Oxford) 55: 252–262, 2016 - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical